News & Investors

Investor Relations

Corporate Profile

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit.

Stock Price

Dec 5, 2022 5:23 AM EST

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News
Oct 14, 2022
Novo Nordisk announces the completion of the Forma Therapeutics acquisition
Sep 30, 2022
Sickle Cell Disease Association of America & Partners Launch New PSA to Boost Awareness and Understanding of the Disease
Sep 01, 2022
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
Aug 5, 2022
8:00 AM EDT
Forma Therapeutics Second Quarter 2022 Financial Results and Business Update
Learn more
Jun 9, 2022
2:00 PM EDT
Jefferies Healthcare Conference
Learn more
May 26, 2022
8:00 AM - 10:00 AM EDT
Forma Therapeutics R&D Day
Learn more